RecruitingPhase 1NCT06703606

A Study to Learn About How Changing Therapy From Emicizumab to Marstacimab Affects People With the Severe Hemophilia A.

Studying Hemophilia

Last synced from ClinicalTrials.gov

ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Pfizer
Principal Investigator
Pfizer CT.gov Call Center
Pfizer
Intervention
MARSTACIMAB(drug)
Enrollment
15 enrolled
Eligibility
12-74 years · MALE
Timeline
2025 – 2027

Study locations (4)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT06703606 on ClinicalTrials.gov

Other trials for Hemophilia

Additional recruiting or active studies for the same condition.

See all trials for Hemophilia →

← Back to all trials